Who
Catherine Madigan
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Hemab Therapeutics Holdings; Chief Medical Officer, Syndax Pharmaceuticals.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Mar 2022
- Last trade
- 30 Apr 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Apr 2026filed 4 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,016 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,016 at $0.00 | filing |
| 29 Jan 2026filed 4 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,134 at $0.00 | filing |
| 29 Jan 2026filed 4 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,134 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $3.1M110,000 at $28.55 | filing |
| 1 Mar 2022filed 3 Mar 2022 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.9M180,000 at $16.06 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.